Motor Fluctuations

Articles Collection

  • Movement Disorders
  • Movement Disorders Clinical Practice
MENU 
  • This article collection was made possible by Cynapsus.
  • Cynapsus

Levodopa-carbidopa intestinal gel

Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients

By Angelo Antonini MD, PhD,*, Victor S. C. Fung MBBS, PhD, FRACP, James T. Boyd MD, John T. Slevin MD, MBA, Coleen Hall MS, MBA, Krai Chatamra PhD, Susan Eaton PharmD and Janet A. Benesh BSMT

The purpose of this study was to assess the effect of levodopa-carbidopa intestinal gel (carbidopa-levodopa enteral suspension) in advanced Parkinson’s disease patients with troublesome dyskinesia.

Read More

Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials

By Anthony E. Lang MD, FRCPC,*, Ramon L. Rodriguez MD, James T. Boyd MD, Sylvain Chouinard MD, FRCPC, Cindy Zadikoff MD, Alberto J. Espay MD, John T. Slevin MD, MBA, Hubert H. Fernandez MD, Mark F. Lew MD, David A. Stein MD, Per Odin MD, PhD, Victor S.C. Fung MBBS, PhD, FRACP, Fabian Klostermann MD, PhD, Alfonso Fasano MD, PhD, Peter V. Draganov MD, Nathan Schmulewitz MD, Weining Z. Robieson PhD, Susan Eaton PharmD, Krai Chatamra PhD, Janet A. Benesh BSMT and Jordan Dubow MD

Continuous administration of levodopa-carbidopa intestinal gel (carbidopa-levodopa enteral suspension) through a percutaneous endoscopic gastrojejunostomy is a treatment option for advanced Parkinson disease (PD) patients with motor fluctuations resistant to standard oral medications. Safety data from 4 prospective studies were integrated to assess the safety of this therapy.

Read More

Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: Final 12-month, open-label results

By Hubert H. Fernandez MD*, David G. Standaert MD, PhD*, Robert A. Hauser MD, Anthony E. Lang MD, FRCPC, Victor S.C. Fung PhD, FRACP, Fabian Klostermann PhD, Mark F. Lew MD, Per Odin MD, PhD, Malcolm Steiger MBBS, MD, FRCP, Eduard Z. Yakupov MD, PhD, DMSc, Sylvain Chouinard MD, FRCPC, Oksana Suchowersky MD, FRCPC, FCCMG, Jordan Dubow MD, Coleen M. Hall MS, Krai Chatamra PhD, Weining Z. Robieson PhD, Janet A. Benesh BSMT and Alberto J. Espay MD, MSc

Motor complications in Parkinson’s disease (PD) are associated with long-term oral levodopa treatment and linked to pulsatile dopaminergic stimulation. L-dopa-carbidopa intestinal gel (LCIG) is delivered continuously by percutaneous endoscopic gastrojejunostomy tube (PEG-J), which reduces L-dopa-plasma–level fluctuations and can translate to reduced motor complications. We present final results of the largest international, prospective, 54-week, open-label LCIG study…

Read More